Phio Pharmaceuticals reports PH-762 is well tolerated in Phase 1b skin cancer trial
PHIO•Phio Pharmaceuticals presented final Phase 1b results for PH-762, which suggested the treatment was well tolerated and may spare tissue when used before surgery for cutaneous squamous cell carcinoma. The company plans a Phase 2b trial in the first half of 2027.
1. Trial findings
Phio Pharmaceuticals presented final Phase 1b results for PH-762 at the American Society for Dermatologic Surgery meeting held November 5-8, 2026. The findings suggested the treatment was well tolerated and may spare tissue when used before surgery for cutaneous squamous cell carcinoma; further studies are needed to assess safety and efficacy. A Phase 2b trial is planned for the first half of 2027.
